Skip to main content

Table 1 Detailed characteristics of patients and tumors

From: Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

Patient Initials

Gender

Age (years)

Mucinous component>50%

Primary tumor

Grading

Stage at diagnosis

pT

FcgRIIIA

FcgRIIA

PFS (months)

First-line CT

Response to first-line CT

Anti-EGFR therapy

Response to anti-EGFR therapy

IN

Female

57

Yes

Colon

3

4

3

158V/V (G/G)

131H/H (A/A)

20,0

FU+IRI+BEV

PR

CET

PR

MM

Female

50

No

Rectum

3

4

NA

158V/F (G/T)

131H/R (A/G)

12,1

CAPE+OXA+BEV

NA

CET

SD

SU

Male

38

No

Rectum

2

3

2

158V/V (G/G)

131H/R (A/G)

17,9

FU+IRI+BEV

PR

CET

PR

RAM

Female

70

Yes

Rectum

2

1

2

158V/F (G/T)

131H/H (A/A)

10,2

FU+OXA+BEV

CR

CET

SD

AA

Female

77

No

Colon

3

4

3

158V/F (G/T)

131H/H (A/A)

6,9

FU+OXA+BEV

SD

CET

SD

MC

Male

67

No

Rectum

3

4

4

158V/V (G/G)

131H/R (A/G)

6,6

CAPE+OXA+BEV

PD

CET

SD

MU

Male

82

NA

Colon

2

3

3

158V/V (G/G)

131H/R (A/G)

NP

CAPE+OXA+BEV

SD

No

NA

AN

Female

76

No

Colon

2

4

NA

158V/V (G/G)

131H/H (A/A)

NP

CAPE+OXA+BEV

PR

No

NA

VA

Female

60

No

Colon

3

4

NA

158V/F(G/T)

131H/R (A/G)

12,1

CAPE+OXA+BEV

PR

No

NA

GA

Female

70

No

Colon

3

4

4

158V/V (G/G)

131H/R (A/G)

18,2

CAPE+OXA

PR

CET

SD

SA

Female

62

NA

Rectum

3

4

3

158V/F (G/T)

131H/R (A/G)

6,4

FU+IRI+BEV

PD

CET

PD

PG

Male

75

No

Colon

3

1

2

158F/F (T/T)

131H/R (A/G)

14,8

FU+OXA

PR

PAN

PR

LRB

Male

61

No

Colon

1

3

3

158F/F (T/T)

131H/R (A/G)

7,7

FU+IRI+BEV

SD

CET

SD

VA

Male

71

No

Colon

2

4

NA

158V/V (G/G)

131H/R (A/G)

8,8

CAPE+OXA+BEV

PD

No

NA

SG

Male

55

No

Colon

2

4

NA

158V/V (G/G)

131H/H (A/A)

19,7

FU+IRI+BEV

PD

No

NA

MR

Female

61

No

Colon

3

4

NA

158V/V (G/G)

131H/R (A/G)

10,8

CAPE+OXA+BEV

SD

No

NA

MMG

Female

43

No

Colon

2

3

4

158V/V (G/G)

131H/H (A/A)

16,1

FU+OXA+BEV

PR

PAN

PR

MM

Male

74

No

Colon

2

4

3

158V/F (G/T)

131H/H (A/A)

NP

FU+IRI+BEV

SD

No

NA

GM

Male

72

No

Rectum

3

4

NA

158F/F (T/T)

131H/R (A/G)

2,6

CAPE+BEV

SD

PAN

NA

LCR

Male

74

No

Rectum

3

3

3

158V/V (G/G)

131H/R (A/G)

23,0

CAPE

CR

CET

PR

BG

Female

47

No

Colon

3

4

NA

158F/F (G/T)

131H/R (A/G)

NP

CAPE+OXA+BEV

CR

No

NA

LG

Female

56

No

Colon

3

3

3

158V/V (G/G)

131H/R (A/G)

22,4

FU+IRI+BEV

PD

CET

SD

DMV

Male

65

No

Colon

2

3

3

158V/F (G/T)

131H/R (A/G)

22,8

CAPE+OXA+BEV

PR

CET

PR

FA

Female

66

No

Colon

2

4

4

158V/F (G/T)

131H/H (A/A)

10,0

FU+IRI+BEV

PR

CET

PR

GF

Male

56

No

Colon

3

4

NA

158V/F (G/T)

131H/H (A/A)

NP

FU+IRI+BEV

PR

No

NA

MA

Female

55

No

Rectum

2

4

NA

158V/F (G/T)

131H/H (A/A)

NP

CAPE+OXA+BEV

PR

No

NA

MMR

Female

54

No

Rectum

2

1

2

158V/F (G/T)

131H/H (A/A)

NA

FU+IRI+BEV

SD

No

NA

LS

Female

58

No

Colon

3

1

NA

158V/F (G/T)

131H/R (A/G)

15,6

FU+IRI+BEV

PR

CET

PR

CD

Male

64

No

Rectum

3

4

NA

158V/F (G/T)

131H/R (A/G)

7,0

FU+IRI+BEV

CR

CET

PR

VE

Female

56

No

Colon

2

3

3

158V/F (G/T)

131H/H (A/A)

38,0

FU+IRI+BEV

PR

CET

PR

VA

Male

81

No

Colon

2

4

NA

158V/V (G/G)

131H/R (A/G)

8,9

FU+IRI+BEV

PR

CET

SD

CM

Female

75

No

Colon

2

2

3

158V/F (G/T)

131H/H (A/A)

9,8

CAPE+OXA+BEV

SD

PAN

PR

IG

Male

73

No

Colon

3

3

NA

158V/F (G/T)

131H/H (A/A)

19,5

FU+IRI+BEV

SD

CET

CR

DGS

Male

63

No

Rectum

1

4

NA

158V/V (G/G)

131H/R (A/G)

7,7

CAPE+OXA

CR

CET

PD

RO

Female

47

No

Rectum

2

3

4

158V/F (G/T)

131R/R(G/G)

9,2

CAPE+OXA

PR

CET

SD

VA

Male

79

No

Colon

2

4

NA

158V/V (G/G)

131H/R (A/G)

13,3

FU+IRI+BEV

PR

CET

SD

DFC

Male

64

NA

Colon

2

4

3

158V/F (G/T)

131H/R (A/G)

21,3

CAPE+BEV

PR

CET

SD

EI

Female

64

No

Colon

2

4

NA

158V/F (G/T)

131H/H (A/A)

16,2

CAPE+OXA+BEV

PR

No

NA

DAR

Female

66

Yes

Colon

2

4

NA

158V/F(G/T)

131H/H (A/A)

NP

CAPE+OXA+BEV

CR

No

NA

BT

Male

56

No

Rectum

2

4

NA

158V/V (G/G)

131H/R (A/G)

NP

FU+IRI+BEV

PR

No

NA

CAG

Female

54

No

Rectum

2

3

4

158V/V (G/G)

131H/H (A/A)

11,7

CAPE+IRI+BEV

PR

CET

PR

DV

Female

78

No

Colon

3

3

3

158V/F (G/T)

131H/R (A/G)

43,6

FU+IRI+BEV

PR

CET

PR

BG

Male

65

No

Colon

3

4

NA

158V/F (G/T)

131H/H (A/A)

18,3

FU+IRI+BEV

SD

CET

PR

NG

Male

80

No

Colon

2

4

NA

158F/F (T/T)

131H/H (A/A)

5,4

FU

PD

No

NA

NR

Female

42

No

Colon

3

4

NA

158V/F(G/T)

131H/R (A/G)

6,7

CAPE+OXA+BEV

PD

No

NA

MR

Male

60

No

Colon

3

4

3

158V/F (G/T)

131H/R (A/G)

8,7

FU+IRI+BEV

PR

CET

SD

SF

Female

62

No

Rectum

2

4

NA

158V/F (G/T)

131R/R(G/G)

14,2

CAPE

SD

CET

SD

DCM

Male

60

No

Colon

2

4

NA

158V/F (G/T)

131H/R (A/G)

37,5

FU+IRI+BEV

PR

CET

PR

CML

Female

44

No

Colon

3

3

3

158V/F (G/T)

131H/R (A/G)

29,3

CAPE+OXA+BEV

CR

CET

PR

BM

Male

66

No

Rectum

3

4

NA

158V/V (G/G)

131H/R (A/G)

8,1

CAPE+BEV

SD

CET

SD

MI

Female

40

NA

Colon

2

4

NA

158V/V (G/G)

131H/R (A/G)

NP

FU+IRI+BEV

PR

No

NA

GC

Female

57

No

Rectum

2

4

NA

158V/V (G/G)

131H/H (A/A)

NP

CAPE+OXA+BEV

PR

No

NA

SC

Male

53

No

Rectum

3

4

NA

158V/V (G/G)

131H/R (A/G)

NP

CAPE+OXA+BEV

SD

No

NA

RR

Male

77

No

Colon

2

2

1

158V/F (G/T)

131H/R (A/G)

9,4

FU+OXA+BEV

PR

PAN

SD

GA

Female

70

No

Colon

3

4

4

158V/V (G/G)

131H/R (A/G)

14,6

CAPE+OXA

PR

No

SD

MP

Male

78

No

Colon

3

4

3

158V/F (G/T)

131H/R (A/G)

9,6

CAPE+OXA+CET

SD

CET

SD

CM

Male

67

No

Rectum

3

3

3

158V/V (G/G)

131H/H (A/A)

43,6

IRI+CET

CR

CET

SD

FR

Female

55

Yes

Rectum

3

4

NA

158V/V (G/G)

131R/R(G/G)

12,4

CAPE+OXA

SD

CET

SD

GL

Male

74

Yes

Colon

2

4

NA

158V/V (G/G)

131H/H (A/A)

NP

FU+OXA+BEV

PR

No

NA

TMA

Female

66

No

Colon

1

4

NA

158V/V (G/G)

131H/R (A/G)

NP

FU+IRI+BEV

PR

No

NA

CF

Female

71

NA

Rectum

2

4

NA

158V/V (G/G)

131H/R (A/G)

NP

CAPE+IRI+BEV

PR

No

NA

CE

Female

55

No

Colon

1

1

4

158V/V (G/G)

131R/R(G/G)

6,1

CAPE+IRI+CET

SD

CET

SD

SME

Male

63

No

Colon

3

4

4

158V/V (G/G)

131H/R (A/G)

NP

CAPE+IRI+CET

PR

CET

PR

GM

Male

56

No

Rectum

3

4

4

158F/F (T/T)

131H/H (A/A)

7,2

CAPE+OXA+CET

PR

CET

PD

IP

Male

69

No

Rectum

3

4

NA

158V/V (G/G)

131H/H (A/A)

7,8

CAPE+OXA

PR

CET

PR

TMR

Female

68

Yes

Colon

3

4

NA

158V/V (G/G)

131H/R (A/G)

8,8

CAPE+OXA+CET

PD

CET

SD

PM

Female

77

No

Colon

1

3

3

158F/F (T/T)

131H/H (A/A)

9,4

CAPE+OXA

CR

CET

PD

MG

Male

64

No

Rectum

3

4

NA

158V/F (G/T)

131H/H (A/A)

16,5

IRI+CET

PD

CET

SD

MG

Male

68

No

Colon

3

4

NA

158V/F (G/T)

131H/H (A/A)

2,8

CAPE+OXA

PD

CET

PD

PG

Male

64

No

Rectum

3

2

3

158V/F (G/T)

131H/H (A/A)

37

FU

PR

CET

SD

SS

Male

82

No

Rectum

3

4

NA

158V/F (G/T)

131H/R (A/G)

19,4

CAPE

PR

CET

PD

FP

Male

69

Yes

Colon

3

4

NA

158V/F (G/T)

131H/R (A/G)

20,8

FU+IRI

SD

CET

PR

PA

Female

70

NA

Colon

2

4

3

158V/F (G/T)

131H/H (A/A)

23,3

CAPE+OXA

CR

No

NA

DLA

Male

82

No

Colon

3

3

2

158F/F (T/T)

131H/R (A/G)

28,0

CAPE+OXA

SD

CET

PD

  1. CT: Chemotherapy: NA: Not Assessable; NP: Not Progressed; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease; PFS: Progression Free Survival; FU: Fluorouracile; IRI: Irinotecan; CAPE: Capecitabine; BEV: Bevacizumab; PAN: Panitumumab; CET: Cetuximab.